ACSS2 and neoplasm: The inhibition of acetyl-CoA synthetase (ACSS2) and long-chain acyl-CoA synthetase 4 (ACSL4) has resulted in a marked decrease in tumour growth and therapeutic sensitivity in various cancers (Table 1).